Printer Friendly

Genaera Announces Patent Issued for Interleukin-9 Receptor.

Genaera Corporation (Plymouth Meeting, PA) said the United States Patent and Trademark Office issued United States Patent 6,645,492 covering claims related to treating asthmatic symptoms by administering an antibody specific for interleukin-9 receptor. The patent is entitled, "Methods for Treating Asthma with Interleukin-9 Receptor Antibodies."

"This further strengthens our patent portfolio for methods to treat interleukin-9 related conditions," noted Roy C. Levitt, M.D., President and Chief Executive Officer.

Genaera is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Research and development efforts are focused on anti-angiogenesis and respiratory diseases. Genaera has three products in development addressing substantial unmet medical needs in major pharmaceutical markets. These include squalamine, an anti-angiogenesis treatment for eye disease and cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN, a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.

Genaera Corporation

+1-610-941-4020

www.genaera.com
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Nov 1, 2003
Words:166
Previous Article:Innovative Biosensors licenses biosensor technology from MIT.
Next Article:Reliant acquires Abbott's antiarrhythmic.
Topics:


Related Articles
Synaptic awarded patent for receptor linked to pain, blood pressure and other functions.
Pfizer obtains United States patent.
Arena Pharmaceuticals receives United States patent.
Genaera announces patent issued protecting interleukin-9.
Sirna Therapeutics granted two key patents on its RNA interference technology.
Targepeutics announces patent issuance for targeted brain cancer compounds.
Sirna Therapeutics obtains patents covering siRNAs targeting VEGF and HCV.
Sirna granted patent covering RNAi-mediated inhibition of gene expression.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters